Axon Enterprise, Inc $AXON Shares Sold by Heartland Bank & Trust Co

Heartland Bank & Trust Co decreased its position in Axon Enterprise, Inc (NASDAQ:AXON) by 51.3% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 284 shares of the biotechnology company’s stock after selling 299 shares during the period. Heartland Bank & Trust Co’s holdings in Axon Enterprise were worth $235,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. TCTC Holdings LLC lifted its holdings in shares of Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 24 shares during the period. Bartlett & CO. Wealth Management LLC lifted its holdings in shares of Axon Enterprise by 132.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 33 shares during the period. Banque Transatlantique SA acquired a new stake in shares of Axon Enterprise in the first quarter valued at $31,000. Catalyst Capital Advisors LLC acquired a new stake in shares of Axon Enterprise in the first quarter valued at $32,000. Finally, Flaharty Asset Management LLC acquired a new stake in shares of Axon Enterprise in the first quarter valued at $33,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $704.67 on Wednesday. Axon Enterprise, Inc has a 1-year low of $422.38 and a 1-year high of $885.91. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $55.32 billion, a price-to-earnings ratio of 173.99, a P/E/G ratio of 27.57 and a beta of 1.41. The stock’s fifty day simple moving average is $751.62 and its 200-day simple moving average is $715.98.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. During the same quarter in the previous year, the company posted $1.20 earnings per share. Axon Enterprise’s revenue for the quarter was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other news, President Joshua Isner sold 15,919 shares of Axon Enterprise stock in a transaction on Friday, August 15th. The stock was sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the transaction, the president owned 238,379 shares in the company, valued at approximately $177,892,712.54. The trade was a 6.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction on Monday, August 11th. The shares were sold at an average price of $831.29, for a total value of $8,312,900.00. Following the transaction, the chief executive officer owned 3,053,982 shares in the company, valued at $2,538,744,696.78. This represents a 0.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,932 shares of company stock valued at $45,115,616 in the last ninety days. Company insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. JPMorgan Chase & Co. upped their price objective on Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a report on Thursday, July 17th. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. Piper Sandler initiated coverage on Axon Enterprise in a research report on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $870.00 target price on shares of Axon Enterprise in a research report on Wednesday, September 24th. Finally, Zacks Research lowered Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.